Curis is an oncology-focused drug developmentcompany seeking to develop novel drug candidates for the treatment of human cancers. The company is committed to leverage its expertise in targeting signaling pathways to advance novel drug candidates for the treatment of various cancers. Our proprietary pipeline includes two clinical stage targeted cancer programs: CUDC-427, a small molecule IAP antagonist and CUDC-907, a dual PI3K and HDAC inhibitor. Our most advanced program, a Hedgehog pathway inhibitor program developed in collaboration with Genentech (Roche), led to the commercialization of ErivedgeŽ (vismodegib), the first and only FDA-approved medicine for the treatment of advanced basal cell carcinoma. Genentech/Roche are responsible for the development and worldwide commercialization of Erivedge. Our collaborator Debiopharm is developing Curis-discovered HSP90 inhibitor Debio 0932 in clinical testing.